Consensus estimates for Vir Biotechnology point to a Q3 2026 revenue of approximately $0.86 million and an EPS loss of $0.74, while the stock currently trades around $11.57, well below the average analyst price target of $21.86.
Investors are primarily focused on pipeline updates regarding the company’s chronic hepatitis delta virus (HDV) franchise and the anticipated timing for Phase 3 ECLIPSE 1 topline data.
Following a significant revenue beat in Q2 due to collaboration milestones, analysts are looking for stability in the core R&D spend and cash runway, which currently extends into 2028.
Recent board appointments and oncology collaborations like the $240 million Astellas deal highlight the company’s shift toward clinical execution and strategic partnerships.